培米加替尼

培米加替尼（CAS 1513857-77-6）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. It is also indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.Pemigatinib is a fibroblast growth factor (FGF) receptor kinase inhibitor that is used to treat unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma, as well as myeloid or lymphoid neoplasms with FGFR rearrangements. Pemigatinib is associated with transient and usually mild-to-moderate elevations in serum aminotransferase levels during therapy, but has not been convincingly linked to cases of clinically apparent liver injury with jaundice.

同义词与商品名

Pemigatinib; 1513857-77-6; Pemazyre; INCB054828; Fgfr inhibitor INCB054828; Y6BX7BL23K; INCB-054828; DTXSID501027955; pemigatinibum; RefChem:58318; DTXCID401513523; Pemigatinib [INN]; Pemigatinib [USAN]; INCB54828; INCB-54828; UNII-Y6BX7BL23K

公开数据库对它的描述

Pemigatinib · CAS 1513857-77-6 · C24H27F2N5O4. UNII Y6BX7BL23K.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。